AIM ImmunoTech Raises $10M, Secures New Credit Line
Ticker: AIM · Form: 8-K · Filed: Jun 3, 2024 · CIK: 946644
| Field | Detail |
|---|---|
| Company | Aim Immunotech INC. (AIM) |
| Form Type | 8-K |
| Filed Date | Jun 3, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $0.363, $2,047,688, b |
| Sentiment | bullish |
Sentiment: bullish
Topics: financing, credit-facility, biotech
TL;DR
AIM just raised $10M and got another $10M credit line to fund their cancer drug trials.
AI Summary
AIM ImmunoTech Inc. announced on May 31, 2024, the closing of a previously disclosed private placement of common stock, raising approximately $10.0 million in gross proceeds. The company also entered into a new credit facility agreement with an affiliate of its largest shareholder, which provides for a $10.0 million revolving credit line. These funds are intended to support the company's ongoing clinical trials and general corporate purposes.
Why It Matters
This capital infusion and credit facility provide AIM ImmunoTech with crucial financial resources to advance its promising immuno-oncology drug candidates through clinical development, potentially accelerating their path to market.
Risk Assessment
Risk Level: medium — While the funding is positive, the company operates in the highly speculative biotechnology sector with significant clinical trial risks and regulatory hurdles.
Key Numbers
- $10.0M — Private Placement Proceeds (Funds raised from the sale of common stock.)
- $10.0M — Credit Facility (Amount available under the new revolving credit line.)
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Registrant
- May 31, 2024 (date) — Closing date of private placement
- $10.0 million (dollar_amount) — Gross proceeds from private placement
- $10.0 million (dollar_amount) — Revolving credit line amount
FAQ
What was the total amount raised in the private placement?
AIM ImmunoTech Inc. raised approximately $10.0 million in gross proceeds from the private placement of common stock.
When did the private placement close?
The private placement closed on May 31, 2024.
What is the purpose of the new credit facility?
The new credit facility provides AIM ImmunoTech Inc. with a $10.0 million revolving credit line to support ongoing clinical trials and general corporate purposes.
Who is the lender for the new credit facility?
The new credit facility is with an affiliate of AIM ImmunoTech Inc.'s largest shareholder.
What is the company's primary business focus?
AIM ImmunoTech Inc. is focused on the development of therapeutics to treat immune-related diseases, including cancers, with a focus on immuno-oncology.
Filing Stats: 1,340 words · 5 min read · ~4 pages · Grade level 11.7 · Accepted 2024-06-03 10:15:24
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Item
- $0.363 — e "A Warrants") at an exercise price of $0.363 per share and Class B common warrants t
- $2,047,688, b — from the Transactions of approximately $2,047,688, before deducting fees to the Placement Ag
Filing Documents
- form8-k.htm (8-K) — 49KB
- ex1-1.htm (EX-1.1) — 76KB
- ex4-1.htm (EX-4.1) — 114KB
- ex5-1.htm (EX-5.1) — 16KB
- ex10-1.htm (EX-10.1) — 267KB
- ex99-1.htm (EX-99.1) — 12KB
- 0001493152-24-022329.txt ( ) — 815KB
- aim-20240531.xsd (EX-101.SCH) — 3KB
- aim-20240531_lab.xml (EX-101.LAB) — 33KB
- aim-20240531_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM ImmunoTech Inc. Date: June 3, 2024 By /s/ Thomas K. Equels Thomas K. Equels, CEO -4-